纳米技术在冠心病中的应用

李涛; 钱永军

doi:10.13201/j.issn.1001-1439.2019.04.021

纳米技术在冠心病中的应用

李涛,
钱永军^,

- 四川大学华西医院心脏大血管外科(成都, 610041)
基金项目:
国家“十三五”重点研发专项资助（No：2016YFC1302003）；四川省科技计划重点研发项目（No：2017SZ0056）；四川省卫生和计划生育委员会科研课题（No：17PJ177）

详细信息

通讯作者: 钱永军,E-mail:qianyongjun@scu.edu.cn

中图分类号: R541.4

收稿日期: 2018-10-25

Application of Nanotechnology in Coronary Heart Disease

LI Tao,
QIAN Yongjun^,

- Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu 610041, China

More Information

Corresponding author: QIAN Yongjun, E-mail: qianyongjun@scu.edu.cn

Received Date: 25 October 2018

摘要

摘要: 冠状动脉疾病（CAD）是影响患者健康状况并导致死亡的重要原因之一，给全世界带来了巨大的经济负担。尽管已经研发了多种药物和治疗措施来延迟疾病的进展并改善患者的生活质量，但仍不能修复或再生受损的缺血心肌。而纳米技术为CAD的诊断和治疗提供了另一种全新的发展方向，并且已在靶向药物治疗和生物材料的开发中表现出了优异的性能。本综述将介绍纳米技术在CAD诊断和治疗中的最新应用。
- 纳米技术 /
- 应用 /
- 靶向治疗 /
- 生物材料 /
- 冠心病
Abstract: Coronary artery disease (CAD) is one of the most important causes to affect the health status and cause mortality of patients.At the same time, it causes a huge economic burden to the whole world.Although a variety of therapeutic drugs and measures have been produced to delay the progress of the disease and improve the quality of life of patients, but most of these cannot repair or regenerate the damaged ischemic myocardium.Nanotechnology provides an alternative and novel direction for the diagnosis and treatment of CAD, and shows excellent performance in the field of targeted drug therapy and the development of biomaterials.This review will briefly introduce the latest applications of nanotechnology in the diagnosis and treatment of CAD.
- nanotechnology /
- application /
- targeted therapy /
- biomaterials /
- coronary heart disease

HTML全文

参考文献(32)

[1]	Brito L, Amiji M.Nanoparticulate carriers for the treatment of coronary restenosis[J].Int J Nanomedicine, 2007, 2(2):143-61.
[2]	陈伟伟, 高润霖, 刘力生, 等.中国心血管病报告2017概要[J].中国循环杂志, 2018, 33(1):1-8.
[3]	Tibbals HF.Medical Nanotechnology and Nanomedicine[M].2010.
[4]	Wong I Y, Bhatia SN, Toner M.Nanotechnology:emerging tools for biology and medicine[J].Genes Dev, 2013, 27(22):2397-2408.
[5]	Karimi M, Zare H, Bakhshiannik A, et al.Nanotechnology in diagnosis and treatment of coronary artery disease[J].Nanomedicine (Lond), 2016, 11(5):513-530.
[6]	Aikawa E, Nahrendorf M, Figueiredo JL, et al.Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo[J].Circulation, 2007, 116(24):2841-2850.
[7]	Flogel U, Ding Z, Hardung H, et al.In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging[J].Circulation, 2008, 118(2):140-148.
[8]	Yeager D, Chen Y, Litovsky S, et al.Intravascular photoacoustics for image-guidance and temperature monitoring during plasmonic photothermal therapy of atherosclerotic plaques:a feasibility study[J].Theranostics, 2013, 4(1):36-46.
[9]	Quillard T, Libby P.Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development[J].Circ Res, 2012, 111(2):231-244.
[10]	Jaffer FA, Libby P, Weissleder R.Molecular imaging of cardiovascular disease[J].Circulation, 2007, 116(9):1052-1061.
[11]	Lewis d R, Kamisoglu K, York A W, et al.Polymer-based therapeutics:nanoassemblies and nanoparticles for management of atherosclerosis[J].Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2011, 3(4):400-420.
[12]	赵培, 陶金, 袁晓晨, 等.冠心病患者PCI术后长期高剂量阿托伐他汀治疗的疗效及安全性[J].临床心血管病杂志, 2017, 33(3):226-230.
[13]	Broz P, Ben-haim N, Grzelakowski M, et al.Inhibition of macrophage phagocytotic activity by a receptor-targeted polymer vesicle-based drug delivery formulation of pravastatin[J].J Cardiovasc Pharmacol, 2008, 51(3):246-252.
[14]	Winter PM, Neubauer AM, Caruthers SD, et al.Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis[J].Arterioscler Thromb Vasc Biol, 2006, 26(9):2103-2109.
[15]	Nakashiro S, Matoba T, Umezu R, et al.Pioglitazone-incorporated nanoparticles prevent plaque destabilization and rupture by regulating monocyte/macrophage differentiation in ApoE-/- Mice[J].Arterioscler Thromb Vasc Biol, 2016, 36(3):491-500.
[16]	Peters D, Kastantin M, Kotamraju V, et al.Targeting atherosclerosis by using modular, multifunctional micelles[J].Proc Natl Acad Sci USA, 2009, 106(24):9815-9819.
[17]	Nakano K, Egashira K, Masuda S, et al.Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology:efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries[J].JACC Cardiovasc Interv, 2009, 2(4):277-283.
[18]	Tsukie N, Nakano K, Matoba T, et al.Pitavastatin-incorporated nanoparticle-eluting stents attenuate in-stent stenosis without delayed endothelial healing effects in a porcine coronary artery model[J].J Atheroscler Thromb, 2013, 20(1):32-45.
[19]	雷凤, 张晓刚.脂肪干细胞对心肌梗死治疗的研究进展[J].临床心血管病杂志, 2017, 33(4):389-392.
[20]	Ding Z, Temme S, Quast C, et al.Epicardium-derived cells formed after myocardial injury display phagocytic activity permitting in vivo labeling and tracking[J].Stem Cells Transl Med, 2016, 5(5):639-650.
[21]	Binsalamah ZM, Paul A, Khan A A, et al.Intramyocardial sustained delivery of placental growth factor using nanoparticles as a vehicle for delivery in the rat infarct model[J].Int J Nanomedicine, 2011, 6:2667-2678.
[22]	Nakano Y, Matoba T, Tokutome M, et al.Nanoparticle-mediated delivery of irbesartan induces cardioprotection from myocardial ischemia-reperfusion injury by antagonizing monocyte-mediated inflammation[J].Sci Rep, 2016, 6:29601.
[23]	Galagudza M, Korolev D, Postnov V, et al.Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles[J].Int J Nanomedicine, 2012, 7:1671-1678.
[24]	徐标, 孙璇.炎症在心肌损伤和修复中的作用[J].临床心血管病杂志, 2018, 34(7):633-635.
[25]	Lozano O, Torres-quintanilla A, García-rivas G.Nanomedicine for the cardiac myocyte:Where are we?[J].J Control Release, 2018, 271:149-165.
[26]	Kim D, Kim P, Song I, et al.Guided three-dimensional growth of functional cardiomyocytes on polyethylene glycol nanostructures[J].Langmuir, 2006, 22(12):5419-5426.
[27]	Aghdam r M, Shakhesi S, Najarian S, et al.Fabrication of a nanofibrous scaffold for the in vitro culture of cardiac progenitor cells for myocardial regeneration[J].Int J Polym Mater, 2013, 63(5):229-239.
[28]	Simon-yarza T, Rossi A, Heffels KH, et al.Polymeric electrospun scaffolds:neuregulin encapsulation and biocompatibility studies in a model of myocardial ischemia[J].Tissue Eng Part A, 2015, 21(9-10):1654-1661.
[29]	Stout d A, Yoo J, Santiago-miranda AN, et al.Mechanisms of greater cardiomyocyte functions on conductive nanoengineered composites for cardiovascular application[J].Int J Nanomedicine, 2012, 7:5653-5669.
[30]	Malki M, Fleischer S, Shapira A, et al.Gold nanorod-based engineered cardiac patch for suture-free engraftment by near IR[J].Nano Lett, 2018, 18(7):4069-4073.
[31]	Lin YD, Yeh ML, Yang YJ, et al.Intramyocardial peptide nanofiber injection improves postinfarction ventricular remodeling and efficacy of bone marrow cell therapy in pigs[J].Circulation, 2010, 122(11 Suppl):S132-141.
[32]	Singelyn J, Dequach J, Seif-naraghi S, et al.Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering[J].Biomaterials, 2009, 30(29):5409-5416.